Skip to main content
Sign In

Matthew Sikora, PhD

Assistant Professor

Education and Traning:​
  • Postdoctoral Research, Women’s Cancer Research Center – University of Pittsburgh Cancer Institute, Pittsburgh, PA (2011-2016)
  • Ph.D., Pharmacology, 2011 – University of Michigan, Ann Arbor, MI (2006-2011)
  • B.S., Genetics and Molecular Biology – University of Michigan, Ann Arbor, MI (2002-2006)

Research Interests:

  • Mechanisms of estrogen receptor (ER) signaling in breast cancer, with a focus on invasive lobular carcinoma (ILC)

  • Mechanisms of resistance to endocrine therapies (ie anti-estrogen drugs)

  • Hormone receptor signaling and transcriptomics during endocrine therapy and the development of resistance to endocrine therapy

  • Development of new therapeutic strategies for breast cancer

Selected Publications: 

For full listings, see or search ‘Sikora MJ’ on Pubmed; further discussion and explanation of our work can be found at

  • Sikora, M.J. Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. Endocrinology. 2016 Dec;157(12):4553-4560. Review. PubMed PMID: 27835038; PubMed Central PMCID: PMC5133350.
  • Sikora, M.J., et al. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cells. In revision, Breast Cancer Research.
  • Sikora, M.J., et al. Endocrine response phenotypes are altered by charcoal-stripped serum variability. Endocrinology. 2016 Jul 26:en20161297. [Epub ahead of print] PubMed PMID: 27459541.
  • Sikora, M.J., et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014;74:1463–74. PMID: 24425047. PMCID: PMC3955299.
  • Sikora, M.J., et al. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids. 2013 Jun;78(6):568-75. PMID: 23178159.
  • Sikora, M.J., et al. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat. 2012;134:1027–39. PMID: 22456984. PMCID: PMC3951731.
  • Sikora, M.J., et al. The Androgen Metabolite 5α-androstane-3β,17β-diol (3βAdiol) Induces Breast Cancer Growth via Estrogen Receptor: Implications for Aromatase Therapy.  Breast Cancer Res Treat. 2009 May;115(2):289-96. PMID: 18521740. PMCID: PMC2728015.